Application-Grade Exosome Manufacturing
OverviewServicesAdvantagesApplicationsFAQs
Overview
Creative BioMart Microbe operates a microbial extracellular vesicle (EV) manufacturing platform built specifically for bacteria and fungi, not adapted from mammalian cell CDMO workflows. We cover the full compliance gradient from small-batch research material to clinical-grade GMP drug substance, with an integrated strain engineering-to-fermentation-to-purification closed loop that eliminates handoff delays between vendors.
Services
Project Workflow
Four-Tier Manufacturing Scale
Research-Grade Exosome Production
High-flexibility, small-batch manufacturing for mechanism discovery and early candidate screening. Volume and strain are configurable per project. Deliverables include liquid suspension or lyophilized powder with batch-specific certificates of analysis.
Food-Grade Exosome Manufacturing
Production under food-ingredient safety protocols with strict control of pathogenic microorganisms, heavy metals, allergens, and endotoxin. Each batch is evaluated for gastrointestinal stability and validated for bioactive function, including anti-inflammatory and barrier-repair activity in cell and animal models. Deliverables are formulated for functional foods, special medical foods, and postbiotic systems.
Cosmetic-Grade Exosome Manufacturing
Manufacturing aligned with cosmetic raw-material regulations, including trace contaminant control and INCI-ready documentation pathways. Downstream efficacy testing is available on keratinocytes and fibroblasts to support claims development. Deliverables include formulation-ready liquid concentrate or lyophilized active ingredients for skincare and dermal repair applications.
GMP-Grade Exosome Manufacturing
Full cGMP production for IND/IMPD-enabling and Phase I/II clinical supply. The platform delivers complete CMC packages, including batch records, validated purification protocols, stability data, and regulatory-compliant QC release panels. Manufacturing scales are transferable from bench to pilot without changing the core strain or purification train.
End-to-End Manufacturing Workflow
Upstream: GMP Fermentation & Culture
The process begins with strain selection from our bank of Gram-negative bacteria, Gram-positive bacteria, and fungi. Fermentation parameters, including medium composition, pH, temperature, dissolved oxygen, and agitation speed, are optimized per strain to maximize EV yield. Because Creative BioMart Microbe maintains an in-house gene-editing platform, the production strain can be engineered for enhanced vesicle secretion, reduced endotoxin burden, or surface display of target ligands before fermentation scale-up begins. This closed-loop strain-to-vesicle capability removes the risk of phenotype drift during external strain handoffs.
Midstream: Optional Cargo Loading & Surface Engineering
For clients requiring functionalized vesicles, we offer integrated loading and surface-modification services using electroporation, heat shock, or co-incubation methods to encapsulate small molecules, nucleic acids, or proteins. Targeting ligands or antibodies can be conjugated chemically or expressed genetically as fusion proteins on the vesicle surface. These modules are managed under the same manufacturing workflow and can be executed at research, cosmetic, or GMP grade. Detailed specifications for these services are maintained on the Exosome Engineering & Drug Loading Services page.
Downstream: GMP Purification
We employ tangential-flow filtration (TFF) combined with size-exclusion chromatography (SEC) as the primary purification train. This approach replaces conventional ultracentrifugation, which creates bottlenecks at scale and generates shear stress that compromises vesicle integrity. The downstream protocol is designed to remove host-cell proteins (HCP), host-cell DNA (HCD), endotoxin, and membrane debris with reproducible recovery rates. For GMP batches, every purification step is documented with in-process controls and traceable filter/chromatography resin lots.
QC Release Testing
Each batch is released against a tiered testing panel matched to its grade:
- Physical characterization: Nanoparticle tracking analysis (NTA) for particle concentration and size distribution; transmission electron microscopy (TEM) for morphology; Zeta potential for surface-charge stability.
- Biochemical profiling: Quantification of outer-membrane proteins (OMP), lipopolysaccharide/lipoteichoic acid (LPS/LTA), total protein, and total lipid content.
- Safety and purity: Sterility, mycoplasma, endotoxin (LAL), host-cell DNA residual, host-cell protein residual, and species-specific identity assays.
- Functional potency: Bioactivity assays tailored to the intended application, including immunomodulation, enzymatic activity, or cell-viability endpoints.
For GMP-grade material, release specifications include project-specific quantitative thresholds for residual HCD and HCP, established during process development and aligned with regulatory expectations (e.g., ICH Q5A residual DNA recommendation of ≤10 ng/dose, with HCP limits set per host-specific ELISA validation).
Detailed Grade Specifications
| Specification |
Research-Grade |
Food-Grade |
Cosmetic-Grade |
GMP-Grade |
| Production Standards |
Laboratory aseptic processing with batch documentation and chain-of-custody records. |
Manufactured under food-ingredient safety frameworks with HACCP-aligned controls. Pathogenic microorganisms, heavy metals, allergens, and endotoxin are monitored per batch. |
Aligned with cosmetic raw-material regulations. Controlled environments with documented environmental monitoring. |
Full cGMP with documented SOPs, batch manufacturing records, and equipment qualification. Facility and process design support FDA, EMA, and other major regulatory agency alignment. |
| Testing Panel |
NTA particle concentration and mean diameter; TEM imaging; Zeta potential; total protein quantification. |
Microbiological safety panel; heavy-metal screening; allergen assessment; endotoxin quantification; simulated gastrointestinal stability; in vivo or in vitro functional validation for anti-inflammatory activity and epithelial barrier repair. |
Microbial limit test; heavy-metal screening; NTA and TEM; cell-level efficacy evaluation on human keratinocytes and fibroblasts for barrier repair, collagen support, or anti-inflammatory readouts. |
Complete QC release: sterility, mycoplasma, endotoxin, NTA particle size distribution, identity assays (species and vesicle-specific markers), purity assessment by orthogonal methods, and potency validation. |
| Delivery Format |
Aseptic liquid suspension in buffered saline or custom buffer; lyophilized format available upon request. |
High-activity liquid concentrate or lyophilized powder with food-grade excipients. |
Formulation-ready liquid active or lyophilized powder optimized for cosmetic compounding and extended shelf stability. |
Clinical-grade bulk drug substance or filled drug product with accompanying CoA, stability summary, and CMC documentation package. |
| Typical Applications |
Mechanism-of-action studies, in vitro uptake and reporter assays, early strain-to-strain comparative screening, and assay development. |
Functional food formulations, special medical foods, probiotic-derived postbiotic ingredients, and oral-delivery nutraceutical systems. |
Premium skincare, dermal repair serums, barrier-enhancement formulations, and cosmetic delivery systems. |
IND-enabling toxicology, Phase I/II clinical trials, advanced therapy medicinal product (ATMP) development, and regulated drug-delivery programs. |
Quality & Compliance Framework
Microbial EVs carry distinct impurity profiles compared to mammalian exosomes. Our quality framework addresses these differences explicitly:
| Control Category |
Key Parameters |
Methodology |
| Microbial Safety |
Sterility, bioburden, mycoplasma, pathogen panel |
USP/EP-compliant culture and PCR methods |
| Endotoxin & Cell-Wall Components |
Endotoxin (LAL), LPS/LTA residual |
Kinetic chromogenic LAL; HPLC/MS profiling |
| Host-Cell Impurities |
HCP, HCD, residual medium components |
ELISA; qPCR; orthogonal detection |
| Vesicle Identity |
OMP profile, particle morphology, mean diameter |
Western blot; TEM; NTA |
| Process Consistency |
Batch-to-batch particle CV%, concentration reproducibility, marker-positive rate |
Statistical process control across defined acceptance criteria |
| Documentation |
Batch manufacturing record (BMR), certificate of analysis (CoA), stability study report |
Reviewed and archived under GMP document control |
For clients advancing from research to GMP, we provide a formal upgrade pathway that locks the master cell bank, master production record, and validated assay panel early, preventing redevelopment at the clinical transition.
Tell us your target application, required grade, and strain preference. Our team will return a customized manufacturing proposal with projected timelines, scale options, and a tiered QC strategy matched to your regulatory pathway.
Our Advantages
- Strain-to-Vesicle Closed Loop In-house microbial genome editing eliminates phenotype drift and accelerates strain-to-GMP timelines.
- Microbial-First, Not Mammalian-Adapted Native bacterial and fungal protocols improve recovery rates and preserve vesicle integrity.
- Multi-Species Strain Flexibility Protocols span Gram-negative, Gram-positive, yeast, and probiotic strains for application-matched manufacturing.
- Scalable Downstream Without Ultracentrifugation TFF-plus-SEC purification scales linearly from bench to pilot with reproducible endotoxin and HCP/HCD clearance.
- Four-Tier Compliance from a Single Platform One platform delivers research through GMP grades with shared assays and seamless vendor-free advancement.
- Quantified Release Standards Quantitative impurity thresholds replace pass/fail language, supporting regulatory filings and predictable formulation.
Applications
Mechanism Discovery & Early Development
Research-grade batches enable uptake assays, reporter-gene delivery, and strain screening, integrated with full characterization and functional validation for complete discovery.
Functional Food & Postbiotic Systems
Food-grade bioactive microbial EVs for oral delivery, with integrated stability and formulation development for GI protection and shelf-life extension.
Cosmetic & Dermal Repair
Cosmetic-grade EVs with in-house skin-cell efficacy testing and INCI documentation, delivering formulation-ready actives from raw to finished.
Therapeutic Drug Delivery & Clinical Development
GMP-grade supply chains support IND-enabling programs with integrated cargo-loading, surface-targeting, and in vivo efficacy validation for clinical development.
FAQs
Q: What distinguishes your microbial exosome manufacturing platform from mammalian exosome CDMO services?
A: Mammalian CDMOs typically adapt mesenchymal stem cell or HEK293 workflows to exosome production. Our platform is engineered specifically for bacteria and fungi, with bioreactor chemistries, fermentation parameters, and purification trains optimized for microbial extracellular vesicles. This native approach improves recovery rates, preserves vesicle integrity, and allows us to handle Gram-negative, Gram-positive, and fungal strains that mammalian facilities cannot process.
Q: Can I start at Research-Grade and upgrade to GMP-Grade without changing the core strain or purification process?
A: Yes. We design the master cell bank, production record, and analytical methods at the research stage so they are transferable to GMP. When you upgrade, the strain lineage, fermentation protocol, and QC assay panel remain locked. This eliminates redevelopment and vendor-switching delays that commonly extend clinical timelines.
Q: What production strains do you support, and can you engineer custom strains for enhanced vesicle secretion?
A: We maintain active protocols for Gram-negative bacteria, Gram-positive bacteria, and yeasts, with dedicated probiotic-strain workflows that span both Gram-positive species (e.g., Lactobacillus, Bifidobacterium) and Gram-negative engineered strains (e.g., E. coli Nissle 1917). Because our in-house gene-editing platform operates upstream of manufacturing, we can knockout, knockdown, or surface-engineer the production strain to increase EV yield, reduce endotoxin burden, or display targeting ligands before the strain enters the GMP workflow.
Q: Why does your downstream process use TFF and chromatography instead of ultracentrifugation?
A: Ultracentrifugation creates scale-up bottlenecks and generates shear stress that compromises vesicle integrity. Our tangential-flow filtration (TFF) plus size-exclusion chromatography (SEC) train is linearly scalable from bench to pilot, delivers reproducible endotoxin reduction, and clears host-cell proteins and DNA with validated recovery rates. It also integrates cleanly into GMP batch records.
Q: What QC release criteria are applied to GMP-Grade batches?
A: GMP-Grade release includes sterility, mycoplasma, endotoxin (LAL), NTA particle size and concentration, identity assays for species and vesicle-specific markers, purity by orthogonal methods, and potency validation. Quantitative acceptance criteria for residual HCD and HCP are set on a project-specific basis—typically HCD ≤10 ng/dose per ICH Q5A and HCP limits established by validated host-specific ELISA—to support regulatory filing consistency.
Q: Can therapeutic cargo loading or surface targeting be integrated into the manufacturing workflow?
A: Yes. Electroporation, heat shock, and co-incubation loading methods can be executed at research, cosmetic, or GMP grade within the same manufacturing run. Surface ligands can be introduced by chemical conjugation or genetic fusion. These modules are managed under the same batch record and QC framework. Detailed specifications are maintained on the Exosome Engineering & Drug Loading Services page.
Q: What documentation is provided with GMP-Grade exosome drug substance?
A: Deliverables include the batch manufacturing record (BMR), certificate of analysis (CoA), stability study summary, validated purification protocol, and a CMC documentation package suitable for IND/IMPD submission. We also provide regulatory consultation support for FDA, EMA, and other major regulatory agency alignment.
Q: What is the typical timeline from strain transfer or engineering to GMP batch release?
A: Timelines depend on strain complexity and grade. A standard Research-Grade batch from an existing strain can be delivered in weeks. For GMP-Grade, the process development, scale-up validation, and QC qualification phases typically span several months. Because the strain-to-purification loop is internal, we avoid the handoff delays common when separate vendors handle strain construction and manufacturing.
Q: Do you support regulatory filings and agency interactions for clinical programs?
A: Yes. Our GMP facility and documentation systems are designed to support FDA, EMA, and other major regulatory agency submissions. We deliver CMC packages, participate in pre-IND meetings as a technical partner, and maintain batch records under GMP document control to withstand regulatory inspection.
Q: How do you control endotoxin and host-cell impurities in bacterial extracellular vesicles?
A: Endotoxin control begins at the strain level, where we can engineer LPS-reduced backgrounds or select low-endotoxin species. Downstream, the TFF-plus-SEC train is validated for endotoxin clearance, and each batch is tested by kinetic chromogenic LAL. Host-cell protein and DNA are monitored by ELISA and qPCR against quantitative release thresholds.
Q: Can I engage your Strain Engineering and Fermentation Optimization services independently of manufacturing?
A: Yes. Strain Engineering & Fermentation Optimization, Exosome Isolation & Purification, and Characterization & Quality Analytics are available as standalone services or integrated into a single manufacturing project. Many clients begin with strain construction and process development, then transfer directly into the manufacturing grade that matches their regulatory stage.
Related Services:
